Progress towards a universal influenza vaccine

Future Virology

Volumn 6, Issue 2, 2011, Pages 237-248

  Ben Yedidia, Tamar ^a  

^a BIONDVAX PHARMACEUTICALS LTD   (Israel)

Author keywords

conserved antigen; epitope; influenza; M2e; pandemic; peptide; seasonal; vaccines

Indexed keywords

ACAM FLU A; ACAMFLU A; AMANTADINE; CHICKENPOX VACCINE; DNA VACCINE; EPITOPE BASED VACCINE; FLU V; FP 01; GAMMAFLU; INFLUENZA VACCINE; LIVE VACCINE; M 001; MATRIX 2 ECTODOMAIN; MEASLES MUMPS RUBELLA VACCINE; MULTIMERIC 001; MULTIPLE; N 8295; NUCLEOPROTEIN; PEPTIDE VACCINE; POLIOMYELITIS VACCINE; RIMANTADINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; UNIVERSAL VACCINE; VGX 3400;

ANTIGEN RECOGNITION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHICKENPOX; CLINICAL TRIAL (TOPIC); CROSS PROTECTION; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG MECHANISM; DRUG TARGETING; EGG; HEALTH HAZARD; HEPATITIS B; HLA SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; LONG TERM CARE; MALARIA; MEASLES; MUMPS; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; RUBELLA; SEASONAL INFLUENZA; SWINE INFLUENZA; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRUS INFECTION; VIRUS MUTATION;

EID: 79952588706     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.80     Document Type: Review

References (85)

1. Nerome R, Hiromoto Y, Sugita S et al.: Evolutionary characteristics of influenza B virus since its first isolation in 1940: dynamic circulation of deletion and insertion mechanism. Arch. Virol. 143(8), 1569-1583 (1998). (Pubitemid 28417788)
2. Belshe R: The need for quadrivalent vaccine against seasonal influenza. Vaccine 28(Suppl. 4), D45-D53 (2010).
3. Bush R.M.: Influenza Evolution. In: Encyclopedic Guide to Infectious Disease Research: Modern Methodologies. Tibayrenc M (Ed.) John Wiley and Sons, NJ, USA 199-214 (2007)
4. Webster R, Laver W, Air G, Schild G: Molecular mechanism of variation in influenza viruses. Nature 296(5853), 115-121 (1982). (Pubitemid 12160907)
5. Receptor Specificity, Host-Range, and Pathogenicity of Influenza Viruses. Matrosovich M, Klenk H, Kawaoka Y (Eds).Caister Academic Press, Norwich, UK (2006)
6. Molinari N, Ortega-Sanchez I, Messonnier M et al.: The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25(27), 5086-5096 (2007). (Pubitemid 46879994)
7. Goodwin K, Viboud C, Simonsen L: Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24(8), 1159-1169 (2006). (Pubitemid 43202262)
8. Clark A, Skypala I, Leech S et al.: British society for allergy and clinical immunology guidelines for the management of egg allergy. Clin. Exp. Allergy 40(8), 1116-1129 (2010).
9. Chung E, Huang L, Schneider L: Safety of influenza vaccine administration in egg-allergic patients. Pediatrics 125(5), E1024-E1030 (2010).
10. Gagnon R, Primeau M, Des Roches A et al.: Safe vaccination of patients with egg allergy with an adjuvanted pandemic H1N1 vaccine. J. Allergy Clin. Immunol. 126(2), 317-323 (2010).
11. Cassone A, Rappuoli R: Universal vaccines: shifting to one for many. MBio. 1(1), PII: E00042-10 (2010).
12. Epstein S, Lo C, Misplon J et al.: Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, b2-microglobulin-deficient, and J chain-deficient mice. J. Immunol. 158(3), 1222-1230 (1997). (Pubitemid 127469945)
13. Skountzou I, Koutsonanos D, Kim J et al.: Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J. Immunol. 185(3), 1642-1649 (2010).
14. Boon A, Debeauchamp J, Krauss S et al.: Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model. J. Virol. 84(15), 7662-7667 (2010).
15. Tu W, Mao H, Zheng J et al.: Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J. Virol. 84(13), 6527-6535 (2010).
16. Furuya Y, Chan J, Regner M et al.: Cytotoxic T cells are the predominant players providing cross-protective immunity induced by g-irradiated influenza A viruses. J. Virol. 84(9), 4212-4221 (2010).
17. Ben-Yedidia T, Beignon A, Partidos C, Muller S, Arnon R: A retro-inverso peptide analogue of influenza virus hemagglutinin B-cell epitope 91-108 induces a strong mucosal and systemic immune response and confers protection in mice after intranasal immunization. Mol. Immunol. 39(5-6), 323-331 (2002). (Pubitemid 35239888)
18. Sambhara S, Kurichh A, Miranda R et al.: Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by flu-iscom vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell. Immunol. 211(2), 143-153 (2001). (Pubitemid 32977345)
19. Bot A, Bot S, Bona C: Protective role of gamma interferon during the recall response to influenza virus. J. Virol. 72(8), 6637-6645 (1998). (Pubitemid 28323981)
20. Scherle P, Gerhard W: Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin. J. Exp. Med. 164(4), 1114-1128 (1986). (Pubitemid 16031610)
21. Russell S, Liew F: Cell cooperation in antibody responses to influenza virus. I. Priming of helper T cells by internal components of virion. Eur. J. Immunol. 10(10), 791-796 (1980). (Pubitemid 11245240)
22. Fan J, Liang X, Horton M et al.: Preclinical study of influenza virus a M2 peptide conjugate vaccines in mice, ferrets and rhesus monkeys. Vaccine 22(23-24), 2993-3003 (2004). (Pubitemid 39037199)
23. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou W, Fiers W: A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10), 1157-1163 (1999). (Pubitemid 29474420)
24. Steel J, Lowen A, Wang T et al.: Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 1(1), PII: E00018-10 (2010).
25. Wei C, Boyington J, Mctamney P et al.: Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329(5995), 1060-1064 (2010).
26. Corti D, Suguitan Aj, Pinna D et al.: Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120(5), 1663-1673 (2010).
27. Quan F, Huang C, Compans R, Nguyen H, Kang S: Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82(3), 1350-1359 (2008).
28. Quan F, Huang C, Compans R, Kang S: Virus-like ppages vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J. Virol. 81, 3514-3524 (2007). (Pubitemid 46456660)
29. Yetter R, Lehrer S, Ramphal R, Small PJ: Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect. Immun. 29(2), 654-662 (1980). (Pubitemid 10040184)
30. Kreijtz J, Bodewes R, Van Den Brand J et al.: Infection of mice with a human influenza A/ H3N2 virus induces protective immunity against lethal infection with influenza A/ H5N1 virus. Vaccine 27(36), 4983-4989 (2009).
31. Schulman J, Kilbourne E: Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J. Bacteriol. 89, 170-174 (1965).
32. Sonoguchi T, Naito H, Hara M, Takeuchi Y, Fukumi H: Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J. Infect. Dis. 151(1), 81-88 (1985). (Pubitemid 15192884)
33. Richards K, Topham D, Chaves F, Sant A: Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J. Immunol. 185(9), 4998-5002 (2010).
34. Jameson J, Cruz J, Terajima M, Ennis F: Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J. Immunol. 162(12), 7578-7583 (1999). (Pubitemid 29277740)
35. Del Giudice G, Stittelaar K, Van Amerongen G et al.: Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci. Transl. Med. 1(12), 12RE1 (2009).
36. Schwarz T, Horacek T, Knuf M et al.: Single dose vaccination with as03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27(45), 6284-6290 (2009).
37. Hans D, Young P, Fairlie D: Current status of short synthetic peptides as vaccines. Med. Chem. 2(6), 627-646 (2006). (Pubitemid 44741618)
38. Rötzschke O, Falk K, Stevanović S, Jung G, Walden P, Rammensee H: Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21(11), 2891-2894 (1991)
39. Ben-Yedidia T, Arnon R: Design of peptide and polypeptide vaccines. Curr. Opin. Biotechnol. 8(4), 442-448 (1997). (Pubitemid 27351281)
40. Snyder J, Belyakov I, Dzutsev A, Lemmonier F, Berzofsky J: Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 78, 7052-7060 (2004). (Pubitemid 38781543)
41. Hsu S, Chargelegue D, Obeid O, Steward M: Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. J. Gen. Virol. 80(Pt 6), 1401-1405 (1999). (Pubitemid 29261470)
42. Azizi A, Diaz-Mitoma F: Viral peptide immunogens: current challenges and opportunities. J. Pept. Sci. 13(12), 776-786 (2007). (Pubitemid 350303215)
43. Kashala O, Amador R, Valero M et al.: Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine spf66 combined with the immunological adjuvant qs-21. Vaccine 20(17-18), 2263-2277 (2002). (Pubitemid 34497037)
44. Nardin E, Oliveira G, Calvo-Calle J et al.: Synthetic malaria peptide vaccine elicits high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182(5), 1486-1496 (2000).
45. Engler O, Dai W, Sette A et al.: Peptide vaccines against hepatitis B virus: from animal model to human studies. Mol. Immunol. 38(6), 457-465 (2001). (Pubitemid 34008475)
46. Gahery H, Daniel N, Charmeteau B et al.: New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses 22(7), 684-694 (2006). (Pubitemid 44061405)
47. Pinto L, Berzofsky J, Fowke K et al.: HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS 13(15), 2003-2012 (1999). (Pubitemid 29509576)
48. Misplon J, Lo C, Gabbard J, Tompkins S, Epstein S: Genetic control of immune responses to influenza A matrix 2 protein (M2).Vaccine 28(36), 5817-5827 (2010).
49. Roth A, Rohrbach F, Weth R, Frisch B, Schuber F, Wels W: Induction of effective and antigen-specific antitumour immunity by a liposomal erbb2/her2 peptide-based vaccination construct. Br. J. Cancer 92(8), 1421-1429 (2005). (Pubitemid 40705009)
50. Ayash-Rashkovsky M, Borkow G, Davis H, Moss R, Bartholomew R, Bentwich Z: Enhanced HIV-1 specific immune response by CPG ODN and HIV-1 immunogen-pulsed dendritic cells confers protection in the trimera murine model of HIV-1 infection. FASEB J. 19(9), 1152-1154 (2005). (Pubitemid 40946448)
51. Honko A, Sriranganathan N, Lees C, Mizel S: Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 74(2), 1113-1120 (2006). (Pubitemid 43185549)
52. Jegerlehner A, Schmitz N, Storni T, Bachmann M: Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172, 5598-5605 (2004). (Pubitemid 38542062)
53. Rosenberg S, Yang J, Schwartzentruber D et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4(3), 321-327 (1998). (Pubitemid 28144091)
54. Lau R, Wang F, Jeffery G et al.: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother. 24(1), 66-78 (2001). (Pubitemid 32103309)
55. Ben-Yedidia T, Marcus H, Reisner Y, Arnon R: Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Int. Immunol. 11, 1043-1051 (1999). (Pubitemid 29338745)
56. Adar Y, Singer Y, Levi R et al.: A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 27(15), 2099-2107 (2009).
57. Hampson A: Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann. Acad. Med. Singapore 37(6), 510-517 (2008).
58. Audsley J, Tannock G: Cell-based influenza vaccines: progress to date. Drugs 68(11), 1483-1491 (2008). (Pubitemid 352001186)
59. Schwartz B, Orenstein W: Prioritization of pandemic influenza vaccine: rationale and strategy for decision making. Curr. Top. Microbiol. Immunol. 333, 495-507 (2009).
60. Harro C, Pang Y, Roden R et al.: Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like ppages vaccine. J. Natl Cancer Inst. 93(4), 284-292 (2001). (Pubitemid 32219815)
61. Bright R, Carter D, Daniluk S et al.: Influenza virus-like ppagess elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin Vaccine 25(19), 3871-3878 (2007). (Pubitemid 46589748)
62. Pushko P, Tumpey T, Van Hoeven N et al.: Evaluation of influenza virus-like ppagess and novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25(21), 4283-4290 (2007). (Pubitemid 46646962)
63. Assarsson E, Bui H, Sidney J et al.: Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J. Virol. 82(24), 12241-12251 (2008).
64. Sirskyj D, Diaz-Mitoma F, Golshani A, Kumar A, Azizi A: Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses. Immunol. Cell Biol. 89(1), 81-89 (2011).
65. Sidney J, Grey H, Kubo R, Sette A: Practical, biochemical and evolutionary implication of the discovery of HLA class I supermotifs. Immunol. Today 17, 261-266 (1996). (Pubitemid 26183489)
66. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A: Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A0201-binding affinity. J. Immunol. 167(2), 787-796 (2001). (Pubitemid 32660833)
67. Ben-Yedidia T, Arnon R: Towards an epitope-based human vaccine for influenza. Hum. Vaccin. 1(3), 95-101 (2005).
68. Thomson S, Elliott S, Sherritt M et al.: Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. 157(2), 822-826 (1996). (Pubitemid 26231388)
69. Le T, Drane D, Malliaros J et al.: Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine 19(32), 4669-4675 (2001). (Pubitemid 32800749)
70. Alexander J, Oseroff C, Dahlberg C et al.: A decaepitope polypeptide primes for multiple CD8+ IFN-g and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J. Immunol. 168(12), 6189-6198 (2002). (Pubitemid 34620038)
71. Wanli L, Zou P, Zuqiang L, Yun L, Jian D, Ying-Hua C: High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 23, 366-371 (2004).
72. Rimmelzwaan G, Boon A, Voeten J, Berkhoff E, Fouchier R, Osterhaus A: Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res. 103(1-2), 97-100 (2004). (Pubitemid 38649067)
73. Yoshida R, Igarashi M, Ozaki H et al.: Cross-protective potential of a novel monoclonal antibody directed against antigenic site b of the hemagglutinin of influenza A viruses. PLoS Pathog. 5(3), E1000350 (2009).
74. Ekiert D, Bhabha G, Elsliger M et al.: Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924), 246-251 (2009).
75. Weight AK, Halder J, Alvarez de Cienfuegos L et al.: Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza A virus. J. Pharm. Sci. 100(3), 831-835 (2011).
76. Air G, Laver W: The neuraminidase of influenza virus. Proteins 6(4), 341-356 (1989). (Pubitemid 20036940)
77. Hassantoufighi A, Zhang H, Sandbulte M et al.: A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 28(3), 790-797 (2010).
78. Mcelhaney J, Xie D, Hager W et al.: T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176, 6333-6339 (2006).
79. Forrest B, Pride M, Dunning A et al.: Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin. Vaccine Immunol. 15(7), 1042-1053 (2008). (Pubitemid 352018317)
80. William EP. Fundamental Immunology. Raven Press, NY, USA (1989).
81. Stouffer A, Acharya R, Salom D et al.: Structural basis for the function and inhibition of an influenza virus proton channel. Nature 451(7178), 596-599. (2008). (Pubitemid 351186271)
82. Zebedee S, Lamb R: Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein. Proc. Natl Acad. Sci. USA 86, 1061-1065 (1989). (Pubitemid 19056290)
83. Wang Y, Zhou L, Shi H et al.: Monoclonal antibody recognizing SLLTEVET epitope of M2 protein potently inhibited the replication of influenza A viruses in MDCK cells. Biochem. Biophys. Res. Commun. 385(1), 118-122 (2009).
84. Fiers W, De Filette M, El Bakkouri K et al.: M2e-based universal influenza A vaccine. Vaccine 27(45), 6280-6283 (2009).
85. Grandea AG 3rd, Olsen OA, Cox TC et al.: Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. PNAS 107(28), 12658-12663 (2010).